Bolt Biotherapeutics Q1 2025: operating loss $12.1M; cash $58M; BDC-4182 Phase 1 open

Bolt Biotherapeutics, Inc.

2025-Q1 EPS reported -$0.29 revenue$1,222,000

Collaboration revenue $1.2M (down from $5.3M in Q1 2024) due to completion of Innovent agreement.
R&D expense $9.5M (down from $16.5M); G&A $3.8M (down from $5.8M) reflecting May 2024 restructuring.
Cash balance $58.0M expected to fund operations and milestones through mid-2026.
BDC-4182 Phase 1 dose-escalation study for gastric/gastroesophageal cancer opened for enrollment in April 2025.
Partnering process initiated for BDC-3042 after AACR 2025 data showed favorable safety and biological activity.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.